References
- ARRANZ, M.J., MUNRO, J., SHAM, P. et al. (1998). Meta analysis of studies on variation in 5HT2a receptors and clozapine response. Schizophrenia Research, 32, 93 99.
- BASILE, V.S., MASELLIS, M., BADRI, F., PATERSON, A.D., MELTZER, H.Y., LIEBERMAN, J.A., POTKIN, S.G., MACCIARDI, F. & KENNEDY, J.L. (1999). Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology, 21, 17 27.
- CLOZAPINE STUDY GROUP (1993). The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Clozapine Study Group. British Journal of Psychiatry, 163, 150 154.
- DEBOUCK, C. & GOODFELLOW, P. (1999). DNA microarrays in drug discovery and development. Nature Genetics, 21, 48 50.
- GONZALEZ, F.J., SKODA, R.C., DIMURA, S. et al. (1989). Characterisation of the common genetic defect in humans deficient in debrisoquim metabolism. Nature, 331, 442 446.
- HAGG, S., JOELSSON, L., MJORNDAL, T., SPIGSET, O., OJA, G. & DAHLQVIST, R. (1988). Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Journal of Clinical Psychiatry, 59, 294 299.
- KAY, S.R., OPLER, L.A. & LINDENMAYER, J.P. (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry Suppl, 59 67.
- PRICE-EVANS, D.A. (1993). Genetic factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge: Cambridge University Press.
- SEGMAN, R., NEEMAN, T., HERESCO-LEVY, U., FINKEL, B., KARAGICHEV, L., SCHLAFMAN, M., DOREVITCH, A., YAKIR, A., LERNER, A., SHELEVOY, A. & LERER, B. (1999). Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Molecular Psychiatry, 4, 247 253.
- SPINA, E., ANCIONE, M., DIROSA, A.E., MEDURI, M. & CAPUTI, A.P. (1992). Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. European Journal of Clinical Pharmacology, 42, 347 348.
- STEEN, V.M., LOVLIE, R., MACEWAN, T., & MCCREADIE, R.G. (1997). Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular Psychiatry, 2, 139 145.
- WIRSHING, D.A., SPELLBERG, B.J., ERHART, S.M., MARDER, S.R. & WIRSHING, W.C. (1998). Novel antipsychotics and new onset diabetes. Biological Psychiatry, 44, 778 783.